Enveric Biosciences

Enveric Biosciences is a biotechnology company focused on developing innovative therapeutics aimed at improving the quality of life for patients affected by cancer treatment side effects and mental health disorders. The company is particularly interested in exploring natural compounds, especially cannabinoids, to create novel prescription medications that address unmet medical needs. Enveric's lead program, EB-003, targets depression, anxiety, and addiction disorders through a unique mechanism that promotes neuroplasticity without causing hallucinations. Additionally, the company is advancing EB-002, a synthetic prodrug of psilocin, which is being studied for its potential in treating various psychiatric conditions. Overall, Enveric Biosciences is committed to addressing significant challenges in both oncology and mental health through its research and development efforts.